In the Zzz Zone: The Effects of Z-Drugs on Human Performance and Driving

Naren Gunja

Published online: 2 March 2013
© American College of Medical Toxicology 2013

Abstract Despite their improved pharmacokinetic profile, the Z-drugs, zolpidem, zopiclone, and zaleplon, have a spectrum of adverse effects comparable to benzodiazepines. This review focuses on the impairment from Z-drugs on cognition, behavior, psychomotor performance, and driving ability. Z-drugs are short-acting GABA agonists that reduce sleep latency without disturbing sleep architecture. Bizarre behavioral effects have prompted warnings on the prescription, dispensation, and use of Z-drugs. Psychomotor impairment, falls, and hip fractures are more likely to occur with Z-drugs that have longer half-lives, that are taken at higher-than-recommended doses and when mixed with other psychoactive substances including alcohol. Zopiclone and higher doses of zolpidem are more likely to cause anterograde amnesia than zaleplon. Z-drugs, especially zolpidem, are associated with complex behaviors such as sleepwalking, sleep-driving, and hallucinations. Patients taking zopiclone and zolpidem have an increased risk of motor vehicle collisions, over double that of unexposed drivers. Driving impairment occurs with zopiclone and higher doses of zolpidem but is unlikely to occur after 4 h post-zaleplon administration. The residual effect of Z-drugs on next-day cognitive and psychomotor performance has significant impact on lifestyle, safety, and occupational considerations, including motor vehicle and machine operation. The risk–benefit analysis of Z-drugs in the treatment of insomnia, particularly in the elderly, may not favor treatment due to the increased risks of falls and motor vehicle collisions. Prescribers should warn patients taking Z-drugs

of minimum time thresholds before they operate machinery or drive motor vehicles.

Keywords Zolpidem · Zopiclone · Zaleplon · Automobile driving · Psychomotor performance

Introduction

The Z-drugs, zolpidem, zopiclone, and zaleplon, were developed as hypnotics with improved pharmacokinetics in comparison to benzodiazepines, the traditional treatments for insomnia. Their pharmacology and toxicology have been previously reviewed [1]. Zolpidem, zaleplon, and eszopiclone are the three Z-drugs currently approved by the US Food and Drug Administration (FDA) for the treatment of insomnia [2]. Like benzodiazepines, Z-drugs are GABA_A receptor agonists; however, their clinically attractive properties include short duration of action, non-disturbance of overall sleep architecture, and diminished residual effects during daytime hours [3]. Z-drug doses and pharmacokinetic profiles are shown in Table 1 [4–10]. While they have been studied in the elderly, there is increasing interest in Z-drug effectiveness and residual effects in shift workers, pilots, and military personnel [11].

Residual effects are dose-dependent and vary between hypnotics based on their pharmacokinetic profile. Of considerable concern are falls in the elderly leading to hip fractures, head injuries, and other significant morbidity and mortality. Furthermore, the effect of Z-drugs on next-day human performance and driving impairment has held sharp focus in the public health sphere as well as in forensic and legal circles. In March 2007, the US FDA released a list of 13 drugs for which stronger labeling was recommended regarding the potential risk of complex sleep-related behaviors [12]. These behaviors, discussed further below, involved parasomnias such as sleep-eating and sleep-driving.

N. Gunja
NSW Poisons Information Centre, The Children's Hospital
at Westmead, Sydney, Australia

N. Gunja (✉)
Discipline of Emergency Medicine, Sydney Medical School,
University of Sydney, Sydney, New South Wales, Australia
e-mail: naren.gunja@sydney.edu.au

Table 1 Pharmacokinetic properties of Z-drugs

Z-drug	Dose range (mg)	$T_{\max}$ (h)	Elimination $t_{1/2}$ (h)
Zolpidem IR	5–10	1–2	2.5–3
Zolpidem ER	6.25–12.5	1.5–2.5	2.5–3
Zopiclone	3.75–7.5	1.5–2	5–6
Eszopiclone	1–3	1–1.5	6–7
Zaleplon	5–20	0.7–1.4	~1

References: [4–10]

IR immediate-release preparation, ER extended/controlled-release preparation, $T_{\max}$ time to maximal concentration (hours), $t_{1/2}$ half-life (hours)

Z-drugs were included in the FDA warning list, and this was soon followed by warnings from other drug regulatory agencies across the world, including the Australian Therapeutic Goods Administration [13]. Since then, several epidemiological studies have attempted to quantify the risk of bizarre behaviors from hypnotic drugs and any differential rates of incidence between them.

Following publicity from the FDA and other regulatory authorities in 2007, Z-drug adverse reaction reporting increased due to health professional and consumer awareness of a potential relationship. Since 2007, adverse drug reporting systems in Australia showed higher rates of reports associating zolpidem and various adverse events such as parasomnia, amnesia, hallucinations, and suicidality. However, retrospective analysis suggests that zolpidem was associated with an increased risk of these adverse events compared with other drugs even prior to the media publicity in 2007 [14].

This review focuses on the adverse effect profile of Z-drugs, specifically on their ability to impair human cognition, behavior, next-day performance, and driving ability. Ovid Medline (1980 to Nov. 2012), Embase (1980 to Nov. 2012), and Google Scholar were searched using the terms “zolpidem,” “zopiclone,” “eszopiclone,” and “zaleplon” in combination with “impairment,” “driving,” “fall,” “memory,” “cognitive,” “residual,” “behavior,” “hallucinations,” “sleepwalking,” OR “performance.” Studies relevant to impairment from Z-drugs in humans were retrieved, and the bibliographies of the retrieved articles were searched for further relevant publications.

Effects on Cognition and Behavior

Like benzodiazepines, Z-drugs, particularly zolpidem and zopiclone, appear to have a dose-dependent effect on anterograde amnesia. Notably, there is an inability to remember the parasomnia or complex behavior; this phenomenon has been observed to a much lesser extent with zaleplon [15,

16]. In a healthy volunteer study, zolpidem was found to impair word recall and recognition 6 h after administration in a dose-dependent fashion, with greatest impairment observed at the highest studied dose of 20 mg [17]. In the same study, zaleplon had no effect at doses up to 20 mg. Several other studies have also confirmed that zaleplon has little or no residual effects the following morning, even when taken during the middle of the night for inability to go back to sleep [18–20]. Zopiclone, at a dose of 7.5 mg or higher, has been shown to impair memory and cognitive function using a battery of tests including the digit symbol substitution test, word learning test, and Sternberg memory scanning test [21]. Similar testing has failed to demonstrate residual effects after eszopiclone (3 mg) [22–24]. However, these studies have allowed 8 h of sleep following the dose, an unlikely scenario in insomniacs. A recent study directly comparing zopiclone (3.75 mg) with eszopiclone (3 mg) in a sleep restriction protocol showed significant next-day residual effects from both drugs, though to a slightly lesser extent with eszopiclone [25].

Many of these studies do not simulate real life scenarios in which patients are prescribed Z-drugs on a long-term basis, leading us to question whether chronic use may lead to tolerance of performance-impairing effects. There appears to be some tolerance to memory and psychomotor impairment from benzodiazepines, such as triazolam [26]. There is emerging evidence that this type of tolerance may not occur with Z-drugs. In a unique study where healthy volunteers took extended-release (ER) zolpidem nightly over a 3- to 4-week period, there was significant memory and performance impairment during nocturnal awakening, which did not improve with chronic dosing [27]. Similarly, Frey et al. showed that 5 mg zolpidem caused significant impairment of cognitive function (working memory and mathematical calculations) in both young adults (mean age 22 years) and older adults (mean age 67 years) during nocturnal awakening [28]. Nocturnal awakening may occur in patients with insomnia for several reasons, and middle-of-the-night impairment due to Z-drugs raises patient safety concerns with regard to falls, amnesia, and decision-making capacity.

Postulated mechanisms for Z-drug-induced amnesia include dose-dependent agonist activity at GABA_A receptors that is also proportional to binding affinity. Pharmacokinetic drug interactions with CYP3A4 enzyme substrates may explain why zolpidem and zopiclone have higher incidence of these adverse effects than zaleplon, which has a different metabolic pathway. Another potential explanation for amnesic effects from all hypnotics is their ability to reduce sleep latency and block memory consolidation, that is, the transfer of short-term memory into long-term storage [15, 29]. In this regard, zolpidem has been shown to impair memory consolidation in mice similar to midazolam [30].

Adverse effects of parasomnia, amnesia, and hallucinations associated with zolpidem have been reported in the last decade over and above all other drugs in a health professional and self-reporting system [14]. The odds ratios (OR) for these adverse events were around 14.0–26.3 (95 % CI 9.9–35.2), compared with other hypnotics. Furthermore, the OR increased up to tenfold for parasomnia events following media publicity in 2007. Confirmatory electroencephalographic (EEG) evidence of sleep during these parasomnia events is lacking, hence the uncertainty regarding their differentiation from a confusional arousal state in which amnesia and automatisms may occur. There is also concern that Z-drugs are being prescribed in patients with prior histories of parasomnia or hallucinations. These patients may already have lower thresholds for such adverse events, which are being exacerbated by Z-drug use [31].

Parasomnia includes abnormal behavior or events during sleep, such as nightmares and terrors, sleepwalking (somnambulism), sleep-eating, sleep-talking, sleep-sex, and sleep-driving. Among the Z-drugs, these phenomena have been mainly associated with zolpidem use. Sleep-driving is considered separately below. Tsai et al. reported three female patients with repetitive behaviors (eating and cleaning) associated with anterograde amnesia after commencing zolpidem at doses of 10–15 mg [32]. Anecdotal reports of neuropsychiatric adverse effects from zolpidem have been higher for women, though this may reflect higher milligram-per-kilogram dosing rather than a gender-based sensitivity to zolpidem. Parasomnia cases have also had a female preponderance, though suicidality from zolpidem has a greater association with the male sex [14]. Somnambulism and amnesia from zolpidem appeared to be rare events with isolated case reports and low prevalence in initial post-marketing surveillance. However, a retrospective Taiwanese study in a cohort of psychiatric outpatients found that over 5 % of zolpidem-treated patients had amnesia or somnambulism [33].

Sleep-Driving

Sleep-driving is the act of driving a vehicle in a semi-awake state after getting out of bed during sleep, in which the individual has no memory of the act afterward. Sleep-driving has been characterized as a variant of sleepwalking (somnambulism), a type of parasomnia in which automated behavior may be performed in a partial arousal from sleep, usually in the first few hours. Some have advocated that sleep-driving should be differentiated from Z-drug-related driving impairment, as it is likely a separate phenomenon with a different etiology and pathophysiology; the latter phenomenon is due to the residual effects of Z-drugs impairing driving ability in an awake individual [34]. Prior to 2006, 14 post-marketing cases of sleep-driving were

reported to the FDA, 13 of which were associated with zolpidem therapy and one with zaleplon [35]. As for other parasomnias, reports of sleep-driving associated with Z-drugs increased following media speculation about a causal link.

The main contention with Z-drug-related sleep-driving is the lack of detailed clinical case reports with objective polysomnographic evidence of a parasomnia occurring during sleep. The few case reports in the medical literature relate to zolpidem therapy at doses between 10 and 12.5 mg [36–38]. In these reports, sleep-driving occurred anywhere from a few weeks to 2 years after initiation of zolpidem. From these few cases, it appears that risk factors for the development of sleep-driving associated with zolpidem include concomitant alcohol, or other sedative intake, and pre-existing or co-existing parasomnia, such as sleepwalking. Further research into the pathophysiology of this parasomnia as well as case series with confirmatory objective evidence of sleep-driving are required before a causal link can be ascribed to Z-drugs.

Effects on Psychomotor Performance

Psychomotor adverse effects from the use of hypnotics are a major concern in the elderly. A risk–benefit analysis of hypnotic drug use in elderly insomniacs may not favor treatment. This is primarily due to a higher incidence of falls and motor vehicle collisions in elderly patients on hypnotic drugs. Hypnotics have a small beneficial effect with a number needed to treat of 13 for improved sleep versus a number need to harm of 6 for any adverse event [39].

Residual psychomotor effects from Z-drug use include dizziness, postural instability, ataxia, and falls. In the geriatric population, falls are associated with significant morbidity including fractures, head injuries, and potentially death. The increased risk of psychomotor disturbance from benzodiazepine use has been well reported [40, 41], and the associated costs to the community have been estimated in billions of dollars [42]. In a Korean insurance registry study, zolpidem use increased the risk of hip fractures nearly twofold (OR 1.72, 95 % CI 1.37–2.16) [43]. In this study, zolpidem use was associated with a higher risk than benzodiazepine use. A similar odds ratio for zolpidem use was found in an aged and disabled program database from New Jersey [44].

Balance tests in healthy young volunteers suggest that both zolpidem and zopiclone have a profound dose-dependent effect on postural sway and body balance in the first few hours after intake [17, 18, 45]. This effect correlates with peak plasma levels of these Z-drugs but may persist into the morning. Psychomotor effects are

exacerbated in elderly Z-drug users due to altered pharmacokinetics and increased sensitivity to peak drug action [46]. Although most people will be asleep in the first few hours after Z-drug ingestion, many elderly users may awaken and mobilize, predisposing them to imbalance and falls. Zolpidem, at a dose of 5 mg, induced middle-of-the-night tandem walk failures on a 10-cm-wide beam in older subjects compared with younger ones and controls; in this study, subjects were awakened 2 h after zolpidem administration [28]. The failure of tandem walking occurred in 3 out of 13 younger subjects only in the first few minutes after awakening. However, persistent impairment was seen in older subjects with 2 out of 12 failing the tandem walk 30 min after awakening. This is of considerable concern as zolpidem induces imbalance and ataxia at the reduced dose of 5 mg, recommended for elderly patients.

Psychomotor impairment during middle-of-the-night awakening has not been demonstrated for zaleplon at doses up to 10 mg in laboratory studies [47, 48]. At 20 mg, impairment in psychomotor testing from zaleplon occurs at peak levels, around 1 h post-administration. However by 6 h, no residual psychomotor impairment was observed for these doses of zaleplon [17]. A study in aviation personnel found short-lived (1–2 h) performance impairment from a 10-mg dose of zaleplon [49]. In the same study, zopiclone at a dose of 7.5 mg had significant impact on performance, more than zaleplon or temazepam, up to 6 h post-dose. Another study of 13 military personnel found significant psychomotor and task performance impairment when subjects were woken up 2 h after a 20-mg dose of zolpidem [50]. This was greater than the impairment observed with 10 mg of zolpidem.

Psychomotor impairment, falls, and hip fractures are more likely to occur with zopiclone, with its longer half-life, and with higher-than-recommended doses of zolpidem. Zaleplon impairs psychomotor performance in correlation with its $T_{\max}$ but has negligible residual effect in the morning.

Effects on Driving

With the advent of a 24-h society, shift work, and ever-increasing use of prescription medication, driving while intoxicated with drugs is being encountered with higher frequency than ever before. Cases of suspected driving under the influence of drugs (DUID) increased 18-fold over a 30-year period to 2007 in Finland, with males comprising nearly 90 % of the suspects [51]. Z-drugs and benzodiazepines were implicated in over three quarters of cases, as was poly-drug use. Benzodiazepines were detected in 15.6 % of injured drivers presenting to a trauma center emergency department in Melbourne, Australia [52].

Various jurisdictions around the globe have instituted roadside drug testing and field sobriety tests in a campaign to increase awareness of the problem, improve road safety, and prevent road deaths. Over the last 10 years, Z-drugs have made their way into screening tests for drugs of impairment in injured or deceased drivers. In addition to their ability to impair cognition, memory, and psychomotor performance, Z-drugs produce residual effects on driving performance the day after nocturnal hypnotic administration.

Epidemiology

Use of benzodiazepines has been known to increase the risk of motor vehicle collisions (MVC) since the 1990s. It has also been shown that long-acting benzodiazepines, such as diazepam, clonazepam, and nitrazepam, are more likely to cause MVC than short-acting ones [53]. Hypnotic medication doubled the risk of MVC in a large national population health survey held in Canada [54]. Pharmacoepidemiological studies suggest that there may be an increased risk of MVC with Z-drugs. In a UK study of drivers involved in a first-time MVC, the odds ratio for an accident associated with benzodiazepines (including zopiclone) was 1.62 (95 % CI 1.24–2.12), greater than for any other psychoactive drug [55]. In this study, zopiclone was the only short-acting hypnotic associated with an increased risk of MVC. A Norwegian study found increased risk of MVC with all four hypnotics studied—zolpidem, zopiclone, nitrazepam, and flunitrazepam [56]. Greatest risk was associated with users of flunitrazepam, who had four times the risk of MVC compared with non-users; zolpidem and zopiclone use increased the risk by a factor of 2.2 and 2.3, respectively.

Zopiclone is one of the most prescribed hypnotics in Scandinavia. In a Norwegian study, zopiclone was detected in 1.4 % of randomly tested drivers, a greater prevalence than for any other detected hypnotic [57]. Similarly, in deceased drivers, zopiclone was the most frequently encountered hypnotic drug in post-mortem samples [58]. A French study confirmed the increased risk of MVC for benzodiazepines but failed to demonstrate any increased risk for zopiclone [59]. They did, however, show that MVC risk was associated with inappropriate use of zolpidem, such as taking more than one tablet a day. A meta-analysis of all driving risk studies showed mixed results for zopiclone-related fatality or injury, but a high risk of property damage [60].

As insomnia affects women more than men and hypnotic medication is more likely to be prescribed for women, it may be expected that there is a gender difference in driving effects after Z-drugs. This has only been demonstrated for zolpidem in one study, that is, women drive significantly worse than men after zolpidem at a dose of 10 mg [61].

Driving Impairment

Driving a motor vehicle is a complex task encompassing psychomotor capability, physical space awareness, reaction times, and other areas of human physiology. The psychopharmacological mechanisms that underlie driving impairment from Z-drugs clearly involve GABA-ergic effects, though other neurotransmitter pathways are important in wakefulness and attention [62]. The impairment of driving ability from medications has been studied for over 30 years with the “on-the-road driving test” being validated as the gold standard for such a purpose [62, 63]. Other tests of driving ability include driving simulators, subjective driving assessments, and laboratory tests of psychomotor performance. The on-the-road driving test typically involves a 100-km supervised and video-recorded drive in which deviation from a standard lateral position within the slow lane of a highway is measured. As the car weaves within the lane, a mean lateral position may be calculated over the 100 km, from which the degree of weaving (standard deviation of lateral position (SDLP)) is derived [64]. Depending on the study, the SDLP (measured in centimeters) is around 17–22 cm in drivers administered the placebo treatment.

Measures of driving performance the morning after nocturnal hypnotic use have been studied for all three Z-drugs. The most consistent findings relate to zopiclone-induced driving impairment at a dose of 7.5 mg [21, 64]. Zopiclone, the Z-drug with the longest half-life, impairs driving the morning after middle-of-the-night dosing, or even if taken before sleep as a nocturnal dose. The driving impairment from zopiclone is reliable to the extent that 7.5 mg has been used in various studies as a positive control and benchmark for comparison with other hypnotics [65, 66]. Impaired driving, measured by mean ($\pm$ SEM) SDLP, increased from 18.2 ($\pm$ 0.5) cm in placebo controls to 21.6 ($\pm$ 0.8) cm in subjects dosed with zopiclone 7.5 mg, 10–11 h earlier; this effect was double that of alcohol in subjects with an average blood alcohol concentration (BAC) of 0.03 % [67]. In the same study, zaleplon 10 mg had no effect on mean SDLP scores. A 15-mg dose of zopiclone (twice the recommended dose) may cause persistent driving impairment through to the afternoon, 16 h after nocturnal administration [64]. Next-day driving impairment was not observed 10 h after a nocturnal 3-mg dose of eszopiclone [24].

Zaleplon, when taken at the recommended dose of 10 mg or doubled to 20 mg, has not been shown to impair driving in the morning. Middle-of-the-night doses of zaleplon up to 20 mg also appear to be safe, as long as at least 4 h has passed before getting behind the wheel of a car, a reflection of its ultra-short half-life [17, 18]. Similarly, zolpidem produces little residual driving impairment the morning after a nocturnal dose of 10 mg in healthy adults. However, at a dose of 20 mg, or when taken in the middle of the night,

zolpidem has the ability to significantly impair daytime driving [17, 68]. Two studies of older drivers, aged 55–65 years, revealed residual impairment from zolpidem that persisted 10 h after a 10-mg dose [69, 70]. Overall, driving impairment occurs with zopiclone and higher doses of zolpidem but is unlikely to occur after 4 h post-zaleplon administration.

Forensic and Legal Considerations

While driving impairment from alcohol use has been well established, the effect of psychoactive medication on driving performance has much less epidemiological data. Obtaining drug levels for psychoactive substances from drivers in MVC and injured or deceased drivers may be a method of differentiating prevalence among drugs. While there may be legislation in some countries mandating drug testing of drivers in MVC, obtaining blood for the measurement of drug concentrations in random drivers is difficult due to a high refusal rate [71]. Data collection is improved in some studies by offering monetary incentives and collecting urine or oral fluid samples instead of blood. Oral fluid testing has significant intra- and inter-individual variation, and ratios of oral-to-blood concentrations can be misleading in individual cases. At a population level, oral fluid testing can be a rapid, non-invasive, and acceptable form of collecting drug data in drivers. Another advantage of oral fluid is that it may be a better marker of recent drug use and impairment at the time of oral fluid testing [72]. Oral fluid appears to be reliable for detecting zopiclone in DUID cases, showing good correlation with blood concentrations [73].

A Swedish study examined zolpidem and zopiclone levels in impaired drivers and in post-mortem blood samples from deceased drivers; it showed elevated levels of both Z-drugs, suggestive of supratherapeutic use [74]. Caution should be used when interpreting these levels, as there were considerable variation, overlap with therapeutic concentrations, and potential for drug interactions. Gustavsen et al. demonstrated a clear dose relationship between increasing zopiclone levels and the degree of driving impairment, similar to that for alcohol [75]. The proportion of impaired drivers was roughly equal when the BAC exceeded 0.1 % and zopiclone concentrations were greater than 130 ng/mL. No such relationship was demonstrated for zolpidem in the same study. There are little data on zaleplon levels and driving impairment likely due to low prescription rates and a short detection window.

While many jurisdictions around the world have implemented traffic laws based on legal limits for BAC, such systems are generally not in place for drug concentrations of other CNS depressants or psychoactive medication.

There is strong evidence to link reductions in MVC, traffic injuries, and deaths to decreasing BAC limits [76]. Such studies for benzodiazepines fail to demonstrate a reliable correlation between drug level and extent of driving impairment. While higher benzodiazepine levels correlate with higher risk of MVC and greater driving impairment, significant intra- and inter-individual differences prevent the setting of legal limits as for alcohol [55, 77].

In Norway, legislators have sought to set impairment limits for illicit substances and prescription medications comparable to those set for alcohol. Norway is the first country in the world to set legally binding limits for drugs other than alcohol [78]. Since February 2012, 13 substances including benzodiazepines and 2 Z-drugs have legal limits with graded sanctions; the set limits are not intended to apply to drivers with a valid prescription for the detected medication [79]. Driving impairment thresholds for zolpidem and zopiclone in Norway are shown in Table 2 [58, 73, 74, 80]. Some authors have suggested that per se limits for illicit substances and psychoactive medications are impractical and likely to be ineffective due to inter-individual differences in drug tolerance, poly-drug use, and poor correlation between drug concentration and impairment [81]. It is suggested that field sobriety testing and confirmation of impairment, coupled with valid prescriptions for medication, would be more reliable and objective grounds for a legislative framework.

The International Council on Alcohol, Drugs and Traffic Safety (ICADTS) has classified prescription medications, including Z-drugs, into three categories based on their likelihood of impairing driving performance [82]. These three categories loosely correspond to BAC as follows: category I (unlikely to impair driving or no effect, BAC<0.05 %), category II (likely to produce minor–moderate effects, BAC 0.05–0.08 %), and category III (likely to produce severe or dangerous effects, BAC>0.08 %). ICADTS has categorized zopiclone as category III, while zolpidem and zaleplon are assigned to category II [83, 84]. Both zolpidem and zaleplon may be considered category I if taken at 10 mg and driving occurs after 10 and 5 h post-dose, respectively.

There have been several media stories and reports in case law of defendants claiming diminished liability due to Z-drug use prior to committing a criminal or civil offense. Nearly all of these cases have involved alleged parasomnia associated with zolpidem use. Examples include assault or murder during a sleepwalking episode, property damage or personal injury during sleep-driving, and periods of amnesia during which criminal actions were carried out [85]. Courts are unlikely to look favorably on co-ingested alcohol or illicit substances as they are presumed to have been ingested intentionally with knowledge of their adverse effects. The defendant must demonstrate that the Z-drug was ingested unknowingly and that during the time of the offense he or she was intoxicated involuntarily [86]. The defendant will likely need to show that they had no prior knowledge of the adverse effects of zolpidem. This may be more difficult to prove since the FDA warning in 2007 and strengthened package labeling by manufacturers [87].

In past decades, criminal acts during somnambulism and parasomnia have been given leniency, since the requirements of *actus reus* (guilty act) and *mens rea* (guilty mind) were not entirely fulfilled [88]. These two common law elements substantiating a voluntary act are part of the burden of proof beyond reasonable doubt in many jurisdictions including the USA, UK, and Australia. The American legal system has dealt with the defense of somnambulism inconsistently and connected it with automatisms, unconsciousness, and insanity [89]. The emerging field of sleep physiology and increasing knowledge of sleep disorders, coupled with objective EEG and polysomnographic evidence, may better inform expert discrimination between sleep automatisms and intentional acts.

Summary

Z-drugs, in particular zopiclone, appear to have similar adverse effects to their predecessors, the benzodiazepines. The residual effects on human performance and driving impairment of Z-drugs are derived from their GABA-ergic

Table 2 Z-drug blood concentration (ng/mL) in driving impairment

Z-drug	Therapeutic C_{max} (dose)	Legal limit ^a	Driving impairment ^b	Driving impairment ^c
Zolpidem	100–200 (10 mg)	31	77	184
Zopiclone	60–90 (7.5 mg)	12	23	58

Blood/plasma ratio for zopiclone is 1.0. References: [58, 73, 74, 80]

C_{max} maximal plasma concentration at therapeutic doses (in brackets)

^a Legal limit in Norway

^b Driving impairment lower threshold (whole blood concentration) for graded sanctions in Norway, comparable to BAC 0.05 %

^c Driving impairment higher threshold (whole blood concentration) for graded sanctions in Norway, comparable to BAC 0.12 %

action and pharmacokinetic profiles. Z-drugs, especially zolpidem, are associated with complex behaviors, hallucinations, and memory impairment. The increased risk of falls and motor vehicle collisions is notably significant for elderly insomniacs on Z-drugs. The risk–benefit analysis of Z-drugs for the management of insomnia in the elderly may not favor treatment. Prescribers should warn patients taking Z-drugs of minimum time thresholds before they operate machinery or drive motor vehicles.

Conflict of Interest None

References

- Gunja N (2013) The clinical & forensic toxicology of Z-drugs. *J Med Toxicol*. doi:10.1007/s13181-013-0292-0
- Dang A, Garg A, Rataboli PV (2011) Role of zolpidem in the management of insomnia. *CNS Neurosci Ther* 17(5):387–397
- Wagner J, Wagner ML (2000) Non-benzodiazepines for the treatment of insomnia. *Sleep Med Rev* 4(6):551–581
- Barkin RL (2007) Zolpidem extended-release: a single insomnia treatment option for sleep induction and sleep maintenance symptoms. *Am J Ther* 14(3):299–305
- Drover DR (2004) Comparative pharmacokinetics and pharmacodynamics of short-acting hypnotosedatives: zaleplon, zolpidem and zopiclone. *Clin Pharmacokinet* 43(4):227–238
- George CF (2001) Pyrazolopyrimidines. *Lancet* 358(9293):1623–1626
- Greenblatt DJ, Legangneux E, Harmatz JS et al (2006) Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo. *J Clin Pharmacol* 46(12):1469–1480
- Halas CJ (2006) Eszopiclone. *Am J Health Syst Pharm* 63(1):41–48
- Najib J (2006) Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. *Clin Ther* 28(4):491–516
- Nutt DJ, Stahl SM (2010) Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. *J Psychopharmacol* 24(11):1601–1612
- Paul MA, Gray G, MacLellan M et al (2004) Sleep-inducing pharmaceuticals: a comparison of melatonin, zaleplon, zopiclone, and temazepam. *Aviat Space Environ Med* 75(6):512–519
- US Food and Drug Administration (2007) FDA requests label change for all sleep disorder drug products. <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108868.htm>. Accessed 1 Dec 2012
- Therapeutic Goods Administration (2007) Zolpidem and bizarre sleep related effects. *Aust Adverse Drug React Bull* 26(1):2–3, <http://www.tga.gov.au/pdf/aadrb-0702.pdf>
- Ben-Hamou M, Marshall NS, Grunstein RR et al (2011) Spontaneous adverse event reports associated with zolpidem in Australia 2001–2008. *J Sleep Res* 20(4):559–568
- Dolder CR, Nelson MH (2008) Hypnotosedative-induced complex behaviours: incidence, mechanisms and management. *CNS Drugs* 22(12):1021–1036
- Forrester MB (2006) Comparison of zolpidem and zaleplon exposures in Texas, 1998–2004. *J Toxicol Environ Health A* 69(20):1883–1892
- Verster JC, Volkerts ER, Schreuder AH et al (2002) Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance. *J Clin Psychopharmacol* 22(6):576–583
- Vermeeren A, Danjou PE, O'Hanlon JF (1998) Residual effects of evening and middle-of-the-night administration of zaleplon 10 and 20 mg on memory and actual driving performance. *Hum Psychopharmacol* 13(S2):S98–S107
- Hindmarch I, Patat A, Stanley N et al (2001) Residual effects of zaleplon and zolpidem following middle of the night administration five hours to one hour before awakening. *Hum Psychopharmacol* 16(2):159–167
- Stone BM, Turner C, Mills SL et al (2002) Noise-induced sleep maintenance insomnia: hypnotic and residual effects of zaleplon. *Br J Clin Pharmacol* 53(2):196–202
- Mets MA, de Vries JM, de Senerpont Domis LM et al (2011) Next-day effects of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on highway driving performance, memory functioning, psychomotor performance, and mood in healthy adult subjects. *Sleep* 34(10):1327–1334
- Rosenberg R, Caron J, Roth T et al (2005) An assessment of the efficacy and safety of eszopiclone in the treatment of transient insomnia in healthy adults. *Sleep Med* 6(1):15–22
- Zammit GK, McNabb LJ, Caron J et al (2004) Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. *Curr Med Res Opin* 20(12):1979–1991
- Boyle J, Trick L, Johnsen S et al (2008) Next-day cognition, psychomotor function, and driving-related skills following nighttime administration of eszopiclone. *Hum Psychopharmacol* 23(5):385–397
- Boyle J, Groeger JA, Paska W et al (2012) A method to assess the dissipation of residual hypnotics: eszopiclone versus zopiclone. *J Clin Psychopharmacol* 32(5):704–709
- Stoops WW, Rush CR (2003) Differential effects in humans after repeated administrations of zolpidem and triazolam. *Am J Drug Alcohol Abuse* 29(2):281–299
- Kleykamp BA, Griffiths RR, McCann UD et al (2012) Acute effects of zolpidem extended-release on cognitive performance and sleep in healthy males after repeated nightly use. *Exp Clin Psychopharmacol* 20(1):28–39
- Frey DJ, Ortega JD, Wiseman C et al (2011) Influence of zolpidem and sleep inertia on balance and cognition during nighttime awakening: a randomized placebo-controlled trial. *J Am Geriatr Soc* 59(1):73–81
- Morgan PT, Kehne JH, Sprenger KJ et al (2010) Retrograde effects of triazolam and zolpidem on sleep-dependent motor learning in humans. *J Sleep Res* 19(1 Pt 2):157–164
- Zanin KA, Patti CL, Sanday L et al (2012) Effects of zolpidem on sedation, anxiety, and memory in the plus-maze discriminative avoidance task. *Psychopharmacology (Berl)*. doi:10.1007/s00213-012-2756-3
- Olson LG (2008) Hypnotic hazards: adverse effects of zolpidem and other z-drugs. *Aust Prescr* 31(6):146–149
- Tsai MJ, Tsai YH, Huang YB (2007) Compulsive activity and anterograde amnesia after zolpidem use. *Clin Toxicol (Phila)* 45(2):179–181
- Tsai JH, Yang P, Chen CC et al (2009) Zolpidem-induced amnesia and somnambulism: rare occurrences? *Eur Neuropsychopharmacol* 19(1):74–76
- Pressman MR (2011) Sleep driving: sleepwalking variant or misuse of z-drugs? *Sleep Med Rev* 15(5):285–292
- Southworth MR, Kortepeter C, Hughes A (2008) Nonbenzodiazepine hypnotic use and cases of “sleep driving”. *Ann Intern Med* 148(6):486–487
- Doane JA, Dalpiaz AS (2008) Zolpidem-induced sleep-driving. *Am J Med* 121(11):e5

37. Hoque R, Chesson AL Jr (2009) Zolpidem-induced sleepwalking, sleep related eating disorder, and sleep-driving: fluorine-18-fluorodeoxyglucose positron emission tomography analysis, and a literature review of other unexpected clinical effects of zolpidem. *J Clin Sleep Med* 5(5):471–476
38. Pressman MR (2011) Sleep and drug-impaired driving overlap syndrome. *Sleep Medicine Clin* 6(4):441–445
39. Glass J, Lancot KL, Herrmann N et al (2005) Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. *BMJ* 331(7526):1169
40. Woolcott JC, Richardson KJ, Wiens MO et al (2009) Meta-analysis of the impact of 9 medication classes on falls in elderly persons. *Arch Intern Med* 169(21):1952–1960
41. Vermeeren A (2004) Residual effects of hypnotics: epidemiology and clinical implications. *CNS Drugs* 18(5):297–328
42. Panneman MJ, Goettsch WG, Kramarz P et al (2003) The costs of benzodiazepine-associated hospital-treated fall injuries in the EU: a Pharmo study. *Drugs Aging* 20(11):833–839
43. Kang DY, Park S, Rhee CW et al (2012) Zolpidem use and risk of fracture in elderly insomnia patients. *J Prev Med Public Health* 45(4):219–226
44. Wang PS, Bohn RL, Glynn RJ et al (2001) Zolpidem use and hip fractures in older people. *J Am Geriatr Soc* 49(12):1685–1690
45. Mets MA, Volkerts ER, Olivier B et al (2010) Effect of hypnotic drugs on body balance and standing steadiness. *Sleep Med Rev* 14(4):259–267
46. Verster JC, Volkerts ER, Spence DW et al (2007) Effects of sleep medications on cognition, psychomotor skills, memory and driving performance in the elderly. *Curr Psychiatry Rev* 3(4):281–292
47. Patat A, Paty I, Hindmarch I (2001) Pharmacodynamic profile of zaleplon, a new non-benzodiazepine hypnotic agent. *Hum Psychopharmacol* 16(5):369–392
48. Troy SM, Lucki I, Unruh MA et al (2000) Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance. *J Clin Psychopharmacol* 20(3):328–337
49. Paul MA, Gray G, Kenny G et al (2003) Impact of melatonin, zaleplon, zopiclone, and temazepam on psychomotor performance. *Aviat Space Environ Med* 74(12):1263–1270
50. Storm WF, Eddy DR, Welch CB et al (2007) Cognitive performance following premature awakening from zolpidem or melatonin induced daytime sleep. *Aviat Space Environ Med* 78(1):10–20
51. Ojaniemi KK, Lintonen TP, Impinen AO et al (2009) Trends in driving under the influence of drugs: a register-based study of DUID suspects during 1977–2007. *Accid Anal Prev* 41(1):191–196
52. Ch'ng CW, Fitzgerald M, Gerostamoulos J et al (2007) Drug use in motor vehicle drivers presenting to an Australian, adult major trauma centre. *Emerg Med Australas* 19(4):359–365
53. Hemmelgarn B, Suissa S, Huang A et al (1997) Benzodiazepine use and the risk of motor vehicle crash in the elderly. *JAMA* 278(1):27–31
54. Vingilis E, Wilk P (2012) Medical conditions, medication use, and their relationship with subsequent motor vehicle injuries: examination of the Canadian National Population Health Survey. *Traffic Inj Prev* 13(3):327–336
55. Barbone F, McMahon AD, Davey PG et al (1998) Association of road-traffic accidents with benzodiazepine use. *Lancet* 352(9137):1331–1336
56. Gustavsen I, Bramness JG, Skurtveit S et al (2008) Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam. *Sleep Med* 9(8):818–822
57. Gjerde H, Normann PT, Pettersen BS et al (2008) Prevalence of alcohol and drugs among Norwegian motor vehicle drivers: a roadside survey. *Accid Anal Prev* 40(5):1765–1772
58. Gjerde H, Christophersen AS, Normann PT et al (2011) Toxicological investigations of drivers killed in road traffic accidents in Norway during 2006–2008. *Forensic Sci Int* 212(1–3):102–109
59. Orriols L, Philip P, Moore N et al (2011) Benzodiazepine-like hypnotics and the associated risk of road traffic accidents. *Clin Pharmacol Ther* 89(4):595–601
60. Elvik R (2012) Risk of road accident associated with the use of drugs: a systematic review and meta-analysis of evidence from epidemiological studies. *Accid Anal Prev*. doi:10.1016/j.aap.2012.06.017
61. Verster JC, Roth T (2012) Gender differences in highway driving performance after administration of sleep medication: a review of the literature. *Traffic Inj Prev* 13(3):286–292
62. Riedel WJ, Vermeeren A, Van Boxtel MPJ et al (1998) Mechanisms of drug-induced driving impairment: a dimensional approach. *Hum Psychopharmacol Clin Exp* 13(S2):S49–S63
63. Verster JC, Veldhuijzen DS, Volkerts ER (2004) Residual effects of sleep medication on driving ability. *Sleep Med Rev* 8(4):309–325
64. Verster JC, Veldhuijzen DS, Patat A et al (2006) Hypnotics and driving safety: meta-analyses of randomized controlled trials applying the on-the-road driving test. *Curr Drug Saf* 1(1):63–71
65. Leufkens TR, Lund JS, Vermeeren A (2009) Highway driving performance and cognitive functioning the morning after bedtime and middle-of-the-night use of gaboxadol, zopiclone and zolpidem. *J Sleep Res* 18(4):387–396
66. Verster JC, Spence DW, Shahid A et al (2011) Zopiclone as positive control in studies examining the residual effects of hypnotic drugs on driving ability. *Curr Drug Saf* 6(4):209–218
67. Vermeeren A, Riedel WJ, van Boxtel MP et al (2002) Differential residual effects of zaleplon and zopiclone on actual driving: a comparison with a low dose of alcohol. *Sleep* 25(2):224–231
68. Partinen M, Hirvonen K, Hublin C et al (2003) Effects of after-midnight intake of zolpidem and temazepam on driving ability in women with non-organic insomnia. *Sleep Med* 4(6):553–561
69. Bocca ML, Marie S, Lelong-Boulouard V et al (2011) Zolpidem and zopiclone impair similarly monotonous driving performance after a single nighttime intake in aged subjects. *Psychopharmacology (Berl)* 214(3):699–706
70. Meskali M, Berthelon C, Marie S et al (2009) Residual effects of hypnotic drugs in aging drivers submitted to simulated accident scenarios: an exploratory study. *Psychopharmacology* 207(3):461–467
71. Gjerde H, Normann PT, Christophersen AS et al (2011) Prevalence of driving with blood drug concentrations above proposed new legal limits in Norway: estimations based on drug concentrations in oral fluid. *Forensic Sci Int* 210(1–3):221–227
72. Chu M, Gerostamoulos D, Beyer J et al (2012) The incidence of drugs of impairment in oral fluid from random roadside testing. *Forensic Sci Int* 215(1–3):28–31
73. Vindenes V, Lund HME, Andresen W et al (2012) Detection of drugs of abuse in simultaneously collected oral fluid, urine and blood from Norwegian drug drivers. *Forensic Sci Int* 219(1–3):165–171
74. Jones AW, Holmgren A (2012) Concentrations of zolpidem and zopiclone in venous blood samples from impaired drivers compared with femoral blood from forensic autopsies. *Forensic Sci Int* 222(1–3):118–123
75. Gustavsen I, Al-Sammurraie M, Morland J et al (2009) Impairment related to blood drug concentrations of zopiclone and zolpidem compared to alcohol in apprehended drivers. *Accid Anal Prev* 41(3):462–466
76. Fell JC, Voas RB (2006) The effectiveness of reducing illegal blood alcohol concentration (BAC) limits for driving: evidence for lowering the limit to .05 BAC. *J Safety Res* 37(3):233–243
77. Verster JC, Roth T (2012) Blood drug concentrations of benzodiazepines correlate poorly with actual driving impairment. *Sleep Med Rev*. doi:10.1016/j.smrv.2012.05.004

78. Norwegian Institute of Public Health (2012) New legal limits in traffic for drugs other than alcohol. http://www.fhi.no/eway/default.aspx?pid=238&trg=MainLeft_5895&MainArea_5811=5895:0:15,5123:1:0:0:::0:0&MainLeft_5895=5825:95784::1:5896:1:::0:0. Accessed 30 Jan 2013
79. Vindenes V, Jordbru D, Knapskog AB et al (2012) Impairment based legislative limits for driving under the influence of non-alcohol drugs in Norway. *Forensic Sci Int* 219(1–3):1–11
80. Drover D, Lemmens H, Naidu S et al (2000) Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem. *Clin Ther* 22(12):1443–1461
81. Reisfield GM, Goldberger BA, Gold MS et al (2012) The mirage of impairing drug concentration thresholds: a rationale for zero tolerance per se driving under the influence of drugs laws. *J Anal Toxicol* 36(5):353–356
82. The International Council on Alcohol, Drugs and Traffic Safety (ICADTS) (2007) Categorization system for medicinal drugs affecting driving performance. <http://www.icadts.org/reports/medicinaldrugs1.pdf>. Accessed 2 Dec 2012
83. The International Council on Alcohol, Drugs and Traffic Safety (2007) ICADTS drugs list. <http://www.icadts.org/reports/medicinaldrugs2.pdf>. Accessed on 2 Dec 2012
84. Verster JC, Mets MAJ (2009) Psychoactive medication and traffic safety. *Int J Environ Res Public Health* 6(3):1041–1054
85. Poceta JS (2011) Zolpidem ingestion, automatisms, and sleep driving: a clinical and legal case series. *J Clin Sleep Med* 7(6):632–638
86. Daley C, McNiel DE, Binder RL (2011) “I did what?” Zolpidem and the courts. *J Am Acad Psychiatry Law* 39(4):535–542
87. Weiss KJ, Del Busto E (2010) Sleep-driving and pathological intoxication: saved by the FDA? *Am J Forensic Psychiatry* 31(1):5–15
88. Weiss KJ, Watson C, Markov D et al (2011) Parasomnias, violence and the law. *J Psychiatry Law* 39(2):249–286
89. Horn M (2004) A rude awakening: what to do with the sleepwalking defense? *BCL Rev* 46(1):149–182